NEW YORK--(EON: Enhanced Online News)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO) resulting from allegations that Abeona may have issued materially misleading business information to the investing public.
“ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure.”
On December 12, 2016, Mako Research published a report on SeekingAlpha.com stating that “ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure.” The report also revealed that Abeona’s Executive Chairman and Principal Executive Officer, Steven H. Rouhandeh, was once a managing director at D. Blech & Co., a brokerage firm that was the subject of SEC investigations in the 1990s, and a securities class action that resulted in a settlement of $15 million for investors, relating to allegations that the firm manipulated the price of several biotech stocks through sham transactions that artificially inflated and maintained the market price of the biotech stocks in order to keep the firm’s interest in such stocks afloat. On this news, shares of Abeona fell sharply during intraday trading on December 12, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Abeona investors. If you purchased shares of Abeona please visit the firm’s website at http://www.rosenlegal.com/cases-1009.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.